What is the Buying Price of Senores Pharmaceuticals Share?

The Buying Price of Senores Pharmaceuticals share is 1050.35 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

How to buy Senores Pharmaceuticals Share at Choice?

To buy Senores Pharmaceuticals stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Senores Pharmaceuticals, choose your preferred order type, and place the trade.

What is the PE ratio of Senores Pharmaceuticals Shares?

The Price-to-earnings (P/E) ratio of Senores Pharmaceuticals shares is 38.11. You can compare it with the sector average for relative valuation.

What is the PB ratio of Senores Pharmaceuticals Shares?

The Price to Book (P/B) ratio Senores Pharmaceuticals shares is 5.19. Useful to assess the stock's value relative to its book value.

Is Senores Pharmaceuticals Overvalued?

To assess Senores Pharmaceuticals’s valuation compare Sector P/E, P/B which are 67.24 & 3.49 with sector averages, along with growth rates and financial metrics.

What is the Market Cap of Senores Pharmaceuticals?

The Market Cap of Senores Pharmaceuticals is 4837.24 CR. It indicates the company's size category and trading liquidity.

What is the 52 Week High and Low of Senores Pharmaceuticals Share Price?

The 52 week high and low prices of Senores Pharmaceuticals share price is 1063.8 & 491. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Which sector does Senores Pharmaceuticals belong to?

Senores Pharmaceuticals belongs to the Healthcare sector.

Senores Pharmaceuticals Share price

SENORES

Healthcare Mid Cap

1050.35

95.70 (10.02%)

NSE

BSE

Last updated on 15 May, 2026 | 15:48 IST

BUYSELL

Today's High

1063.80

Today's Low

941.00

52 Week Low

491.00

52 Week High

1063.80

Free Demat with Zero AMC*

Senores Pharmaceuticals Chart

ChartIQ

TradingView

Senores Pharmaceuticals Share Key Metrics

Volume

13.25 L

Market Cap

4837.24 CR

LTQ@LTP

5@1050.35

ATP

1009.78

Var Margin

18.88 %

Circuit Range

763.75-1145.55

Delivery %

29.11 %

Value

133.84 CR

ASM/GSM

No

Market Lot

1

Summary

15 May, 2026 | 15:48 को, Senores Pharmaceuticals का शेयर प्राइस आज ₹1050.35 पर है, जो दिन के लिए 95.70% की 10.02 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹941.00 और ₹1063.80 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹491.00 से ₹1063.80 तक रही है। ट्रेडिंग गतिविधि के मामले में, Senores Pharmaceuticals ने 1325468 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹46053588 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹100978 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 5,105035 रही। यह स्टॉक ₹763.75-1145.55 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹133.84 CR है। दिन के लिए डिलीवरी परसेंटेज 29.11% रही। इसके अतिरिक्त, Senores Pharmaceuticals वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Senores Pharmaceuticals Fundamentals

P/E Ratio

38.11

P/B Ratio

5.19

Div. Yield

0

Sector P/E

67.24

Sector P/B

3.49

Sec. Div. Yield

0.56

Senores Pharmaceuticals Resistance and Support

Pivot 950.6

Resistance

First Resistance

994.6

Second Resistance

1034.55

Third Resistance

1078.55

Support

First Support

910.65

Second Support

866.65

Third Support

826.7

Senores Pharmaceuticals Shareholding Pattern

2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

45.82%

Mutual Fund

5.07%

Insurance

2.96%

Foreign Institutional Investors

3.64%

Domestic Institutional Investors

1.58%

Retail

40.93%

Others

0%

Total Promoters

MAR '26

45.82%

Senores Pharmaceuticals Corporate Actions

Date	Agenda
2026-05-14	Audited Results
2026-01-20	Quarterly Results & Others
2026-01-07	Others

Senores Pharmaceuticals News

Senores Pharmaceuticals Ltd - 544319 - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended On March 31, 2026

Senores Pharma provided an update on the utilization of its Rs. 500 crore IPO funds. A Rs. 33.02 crore capex for its subsidiary, Havix, is delayed to FY27 due to geopolitical issues. Additionally, Rs. 6.31 crore from offer expenses and Rs. 0.40 crore from debt repayment were re-allocated to general corporate purposes and inorganic growth.

May 14 2026 15:05:00

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Senores Pharmaceuticals' Q4 FY26 Monitoring Agency Report highlights delays in deploying IPO proceeds. Significant delays include Rs. 33.02 cr for a manufacturing facility, now extended to FY27, and working capital investments. Funds have been re-allocated between various objectives.

May 14 2026 15:05:00

Senores Pharmaceuticals Ltd - 544319 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Senores Pharmaceuticals released its Q4 and FY26 financial results via a media release, reporting strong performance. Q4 total income increased by 66% to Rs.190 crore and PAT rose 104% to Rs.37 crore. The company also announced strategic acquisitions of Zoraya and Apnar Pharmaceuticals, and a new joint venture in the U.S. Federal Market.

May 14 2026 14:05:00

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Outcome for Outcome Of Board Meeting Held On May 14, 2026

Senores Pharma announced strong Q4 FY26 and full-year FY26 consolidated financial results. Q4 total income grew 66% to ₹190 Cr, EBITDA surged 219% to ₹62 Cr, and PAT increased 104% to ₹37 Cr. The company completed 75% stake acquisition in Apnar Pharmaceuticals and formed a 70% JV, Amerisyn, for the US federal market.

May 14 2026 14:05:00

Senores Pharmaceuticals Ltd - 544319 - Board Meeting Intimation for Considering And Approving The Audited Consolidated And Standalone Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And To Transact Other Business Matters

Senores Pharmaceuticals board is scheduled to meet on May 14, 2026. The primary agenda is to consider and approve the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026.

May 08 2026 17:05:00

Senores Pharmaceuticals Limited

Senores Pharmaceuticals promoters and promoter group confirmed no new encumbrances on company shares during the financial year ended March 31, 2026. This annual disclosure ensures compliance with SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Apr 22 2026 17:04:00

NSE : 28888

BSE : 544319

ISIN : INE0RB801010

Our Company was originally incorporated as “Senores Pharmaceuticals Private Limited” a private limited company under the Companies Act 2013 through certificate of incorporation dated December 26 2017 issued by the Registrar of Companies Central Registration Centre.The name of the Company was thereafter changed to “Senores Pharmaceuticals Limited” upon conversion to a public limited company pursuant to a Board resolution dated August 1 2023 a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24 2023 and the approval of the central government dated September 4 2023 and consequently a fresh certificate of incorporation dated September 4 2023 was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.2022- Started the domestic business with a launch of the critical care injectables2023- Acquired majority stake in Havix. making it a Subsidiary of our Company- Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited making a Subsidiary of our Company.2024- Launched first CMO product in the US with Jubilant Cadista

Name	Position
Vinay Kumar Mishra	Company Secretary & Compliance Officer
Swapnil Jatinbhai Shah	Managing Director

Senores Pharmaceuticals Similar Stocks

Kovai Medical Center & Hospital Ltd.

5427.50

62.50 (1.16%)

Nephrocare Health Services Ltd.

643.95

60.65 (10.40%)

Suven Life Sciences Ltd.

211.15

4.60 (2.23%)

Supriya Lifescience Ltd.

688.55

3.30 (0.48%)

Innova Captab Ltd.

858.30

-13.60 (1.56%)

Artemis Medicare Services Ltd.

279.80

2.38 (0.86%)

Advanced Enzyme Technologies Ltd.

363.75

-1.50 (0.41%)

RPG Life Sciences Ltd.

2292.50

-55.90 (2.38%)

SMS Pharmaceuticals Ltd.

400.40

0.90 (0.23%)

Indraprastha Medical Corporation Ltd.

367.75

-10.80 (2.85%)

Senores Pharmaceuticals FAQs

Senores Pharmaceuticals शेयर का खरीद मूल्य 1050.35 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Senores Pharmaceuticals शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Senores Pharmaceuticals शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 38.11 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Senores Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 5.19 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Senores Pharmaceuticals शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.49 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Senores Pharmaceuticals का मार्केट कैप 4837.24 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Senores Pharmaceuticals शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 1063.80 और 491.00 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।